$20.92
1.497.67%
At Close: -
$20.92
00.00%
After Hours: 4:56 PM EDT
15 minutes delayed
Edgewise Therapeutics
EWTXNASDAQ
want to know what
the Bulls & Bears Say?
Edgewise Therapeutics (NASDAQ:EWTX) Stock, Analyst Ratings, Price Targets, Forecasts
Edgewise Therapeutics Inc has a consensus price target of $28 based on the ratings of 26 analysis. The 3 most-recent analyst ratings were released by Piper Sandler, Wedbush, and RBC Capital on July 1, 2024, June 26, 2024, and April 22, 2024, respectively. With an average price target of $37 between Piper Sandler, Wedbush, and RBC Capital, there's an implied 76.86% upside for Edgewise Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wedbush
RBC Capital
Truist Securities
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Edgewise Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 129.45% | Piper Sandler | Yasmeen Rahimi | $48 → $48 | Maintains | Overweight | Get Alert |
| 06/26/2024 | Buy Now | 48.18% | Wedbush | Laura Chico | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 52.96% | RBC Capital | Leonid Timashev | $28 → $32 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 19.5% | Truist Securities | Srikripa Devarakonda | $25 → $25 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 24.28% | Wedbush | Laura Chico | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 33.84% | RBC Capital | Leonid Timashev | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 129.45% | Piper Sandler | Yasmeen Rahimi | → $48 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 9.94% | Wedbush | Laura Chico | $27 → $23 | Maintains | Outperform | Get Alert |
| 08/16/2023 | Buy Now | 29.06% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | 29.06% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 19.5% | JP Morgan | Tessa Romero | $24 → $25 | Maintains | Overweight | Get Alert |
| 06/28/2023 | Buy Now | 19.5% | Truist Securities | Srikripa Devarakonda | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 33.84% | RBC Capital | Leonid Timashev | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | 19.5% | Truist Securities | Srikripa Devarakonda | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 14.72% | JP Morgan | Tessa Romero | $25 → $24 | Maintains | Overweight | Get Alert |
| 05/12/2023 | Buy Now | 29.06% | Wedbush | Laura Chico | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 05/01/2023 | Buy Now | 19.5% | Truist Securities | Srikripa Devarakonda | → $25 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 19.5% | JP Morgan | Tessa Romero | $27 → $25 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 38.62% | RBC Capital | Leonid Timashev | $31 → $29 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | -76.1% | Goldman Sachs | Madhu Kumar | → $5 | Downgrade | Neutral → Sell | Get Alert |
| 05/24/2022 | Buy Now | -76.1% | Goldman Sachs | Madhu Kumar | $8 → $5 | Maintains | Neutral | Get Alert |
| 05/12/2022 | Buy Now | -61.76% | Goldman Sachs | Madhu Kumar | $11 → $8 | Maintains | Neutral | Get Alert |
| 05/12/2022 | Buy Now | 43.4% | SVB Leerink | Joseph Schwartz | $34 → $30 | Maintains | Outperform | Get Alert |
| 04/13/2022 | Buy Now | 48.18% | RBC Capital | Leonid Timashev | → $31 | Initiates | → Outperform | Get Alert |
| 02/14/2022 | Buy Now | 52.96% | JP Morgan | Tessa Romero | $33 → $32 | Maintains | Overweight | Get Alert |
| 01/06/2022 | Buy Now | 57.74% | JP Morgan | Tessa Romero | $30 → $33 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Edgewise Therapeutics (EWTX) stock?
The latest price target for Edgewise Therapeutics (NASDAQ:EWTX) was reported by Piper Sandler on July 1, 2024. The analyst firm set a price target for $48.00 expecting EWTX to rise to within 12 months (a possible 129.45% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewise Therapeutics (EWTX)?
The latest analyst rating for Edgewise Therapeutics (NASDAQ:EWTX) was provided by Piper Sandler, and Edgewise Therapeutics maintained their overweight rating.
When was the last upgrade for Edgewise Therapeutics (EWTX)?
There is no last upgrade for Edgewise Therapeutics
When was the last downgrade for Edgewise Therapeutics (EWTX)?
The last downgrade for Edgewise Therapeutics Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $5 for Edgewise Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Edgewise Therapeutics (EWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
Is the Analyst Rating Edgewise Therapeutics (EWTX) correct?
While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a maintained with a price target of $48.00 to $48.00. The current price Edgewise Therapeutics (EWTX) is trading at is $20.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.